文献速递神经肿瘤

成人胶质瘤患者术前免疫特征分析

Pre-surgery immune profiles of adult glioma patients.
PubMed 文献 · J Neurooncol · 2022-06-18

该研究分析了139例II/III级胶质瘤或新发胶质母细胞瘤患者及454名无胶质瘤对照者的术前血液样本,通过DNA甲基化阵列估算免疫细胞相对比例。结果显示胶质瘤患者除中性粒细胞升高外,各免疫细胞亚群比例均显著降低,且地塞米松使用与CD4低计数、中性粒细胞升高及NLR升高相关。作者强调免疫特征研究需考虑地塞米松暴露,并尽可能在地塞米松使用前采集免疫指标。

要点

  • 胶质瘤患者术前除中性粒细胞升高外,CD4、CD8、B细胞、NK细胞和单核细胞比例均显著低于对照。
  • 地塞米松使用率在IDH野生型胶质母细胞瘤患者中最高(75%),在少突胶质细胞瘤患者中最低(14%)。
  • 使用地塞米松者更常见CD4低计数(<200、<500)、中性粒细胞升高、绝对淋巴细胞计数低、总细胞计数高及NLR高。

核心结论

  • 术前血液免疫特征随胶质瘤亚型、年龄及地塞米松使用而变化,地塞米松暴露是免疫特征研究中的重要考量因素。
  • 作者认为应尽可能在地塞米松使用前采集免疫指标。

研究设计与样本

  • 研究分析了139例新发或复发II/III级胶质瘤(LrGG,n=64)或新发胶质母细胞瘤(GBM,n=75)患者及454名无胶质瘤对照者的术前血液样本。
  • 通过Illumina EPIC阵列的血液DNA甲基化数据,采用经验证的去卷积算法估算CD4、CD8、B细胞、自然杀伤细胞、单核细胞和中性粒细胞的相对细胞分数。

主要发现

  • 采血时地塞米松使用率因胶质瘤类型而异,IDH野生型(wt)GBM患者最高(75%),少突胶质细胞瘤患者最低(14%)。
  • 与对照相比,胶质瘤患者除中性粒细胞升高外,所有免疫细胞亚群细胞分数均显著降低(所有p值<0.001),部分归因于IDHwt GBM患者采血时地塞米松使用率较高。
  • 使用地塞米松的患者更可能出现CD4计数低(<200、<500)、中性粒细胞升高、绝对淋巴细胞计数低、总细胞计数高及NLR高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although immunosuppression is a known characteristic of glioma, no previous large studies have reported peripheral blood immune cell profiles prior to patient surgery and chemoradiation. This report describes blood immune cell characteristics and associated variables prior to surgery among typical glioma patients seen at a large University practice. METHODS: We analyzed pre-surgery blood samples from 139 glioma patients diagnosed with a new or recurrent grade II/III glioma (LrGG, n = 64) or new glioblastoma (GBM, n = 75) and 454 control participants without glioma. Relative cell fractions of CD4, CD8, B-cells, Natural Killer cells, monocytes, and neutrophils, were estimated via a validated deconvolution algorithm from blood DNA methylation measures from Illumina EPIC arrays. RESULTS: Dexamethasone use at time of blood draw varied by glioma type being highest among patients with IDH wild-type (wt) GBM (75%) and lowest for those with oligodendroglioma (14%). Compared to controls, glioma patients showed statistically significant lower cell fractions for all immune cell subsets except for neutrophils which were higher (all p-values < 0.001), in part because of the higher prevalence of dexamethasone use at time of blood draw for IDHwt GBM. Patients who were taking dexamethasone were more likely to have a low CD4 count (< 200, < 500), increased neutrophils, low absolute lymphocyte counts, higher total cell count and higher NLR. CONCLUSION: We show that pre-surgery blood immune profiles vary by glioma subtype, age, and more critically, by use of dexamethasone. Our results highlight the importance of considering dexamethasone exposures in all studies of immune profiles and of obtaining immune measures prior to use of dexamethasone, if possible.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Bracci PM, Rice T, Hansen HM, et al. Pre-surgery immune profiles of adult glioma patients. J Neurooncol. 2022. PMID: 35716311. doi:10.1007/s11060-022-04047-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。